Richard D. Cummings

Dr. Cummings is the Director of the National Center for Functional Glycomics and Professor in the Department of Surgery at Beth Israel Deaconess Medical Center, Harvard Medical School in Boston. He is an internationally recognized expert in the field of Functional Glycomics and was a Founder of Selexys Pharmaceutical Company in Oklahoma City, OK, which developed SelG1, an anti-P-selectin antibody, based on his research on the structure, function, and glycan binding specificity of P-Selectin. Selysis was acquired by Novartis in 2016 following receipt of results of a Phase II trial evaluating the use of SelG1 in the reduction of vaso-occlusive pain crises in patients with sickle cell disease. Dr Cummings was Dr. Song’s postdoctoral mentor at Emory University School of Medicine, and he and Dr. Smith have been long-time colleagues and collaborators.